Beam Therapeutics (BEAM) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $65.7 million.

  • Beam Therapeutics' Cash from Investing Activities rose 16583.12% to $65.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.6 million, marking a year-over-year decrease of 16603.82%. This contributed to the annual value of $185.0 million for FY2024, which is 15752.64% up from last year.
  • Latest data reveals that Beam Therapeutics reported Cash from Investing Activities of $65.7 million as of Q3 2025, which was up 16583.12% from -$170.4 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Cash from Investing Activities registered a high of $126.3 million during Q4 2024, and its lowest value of -$537.3 million during Q1 2022.
  • In the last 5 years, Beam Therapeutics' Cash from Investing Activities had a median value of -$10.2 million in 2023 and averaged -$38.3 million.
  • Per our database at Business Quant, Beam Therapeutics' Cash from Investing Activities plummeted by 318684.63% in 2023 and then skyrocketed by 34142.72% in 2024.
  • Quarter analysis of 5 years shows Beam Therapeutics' Cash from Investing Activities stood at -$77.5 million in 2021, then skyrocketed by 246.38% to $113.4 million in 2022, then fell by 13.52% to $98.1 million in 2023, then grew by 28.73% to $126.3 million in 2024, then crashed by 48.01% to $65.7 million in 2025.
  • Its Cash from Investing Activities stands at $65.7 million for Q3 2025, versus -$170.4 million for Q2 2025 and -$125.1 million for Q1 2025.